| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc. | Encaleret - (CALIBRATE) | Autosomal Dominant Hypocalcemia Type 1 (ADH1) | NDA Filing | Ongoing | oral | Genetic Disorder |
| BridgeBio Pharma Inc. | BBP-418 - (FORTIFY) | Limb Girdle Muscular Dystrophy Type 2i (LGMD2i) | NDA Filing | Data Released | Oral | Genetic Disorder |
| BridgeBio Pharma Inc. | Infigratinib - (ACCEL) | Hypochondroplasia | Phase 2 | Ongoing | Oral | Genetic Disorder |
| BridgeBio Pharma Inc. | TRUSELTIQ (Infigratinib) | Solid tumors | Phase 2 | Ongoing | Oral | Oncology |
| BridgeBio Pharma Inc. | Patidegib (BBP-009) | Gorlin syndrome | Phase 3 | Ongoing | Topical | Genetic Disorder |
| BridgeBio Pharma Inc. | Acoramidis (AG10) / BBP-265 | ATTR-PN | Phase 3 | Withdrawn | Oral | Neurology |
| BridgeBio Pharma Inc. | TRUSELTIQ (infigratinib)- (PROOF 302) | Urothelial Carcinoma | Phase 3 | Ongoing | Oral | Oncology |
| BridgeBio Pharma Inc. | Encaleret - (RECLAIM-HP) | Chronic hypoparathyroidism | Phase 3 | Trial Planned | oral | Endocrinology |